Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Otonomy Inc (OTIC)

Otonomy Inc (OTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,347
  • Shares Outstanding, K 30,868
  • Annual Sales, $ 600 K
  • Annual Income, $ -44,680 K
  • 60-Month Beta 2.36
  • Price/Sales 187.27
  • Price/Cash Flow N/A
  • Price/Book 3.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.40
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +13.42%
on 07/06/20
4.39 -23.01%
on 07/22/20
+0.22 (+6.96%)
since 07/02/20
3-Month
2.20 +53.64%
on 05/04/20
4.39 -23.01%
on 07/22/20
+0.98 (+40.83%)
since 05/01/20
52-Week
1.53 +120.92%
on 03/19/20
4.39 -23.01%
on 07/22/20
+0.82 (+32.03%)
since 08/02/19

Most Recent Stories

More News
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an exclusive license agreement with KYORIN Pharmaceutical...

OTIC : 3.46 (-1.42%)
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter...

OTIC : 3.46 (-1.42%)
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public...

OTIC : 3.46 (-1.42%)
Otonomy (OTIC) Catches Eye: Stock Jumps 9.1%

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

PCRX : 54.79 (+4.14%)
OTIC : 3.46 (-1.42%)
Otonomy Announces Pricing of $60.1 Million Public Offering

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000...

OTIC : 3.46 (-1.42%)
Otonomy Announces Proposed Public Offering

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering...

OTIC : 3.46 (-1.42%)
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

-- Given clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitus

OTIC : 3.46 (-1.42%)
Otonomy Provides Update on Clinical Trials and Development Programs

-- Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020

OTIC : 3.46 (-1.42%)
Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher

Otonomy (OTIC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

OTIC : 3.46 (-1.42%)
ATXI : 10.30 (+1.68%)
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive...

OTIC : 3.46 (-1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade OTIC with:

Business Summary

Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle...

See More

Key Turning Points

2nd Resistance Point 3.85
1st Resistance Point 3.68
Last Price 3.46
1st Support Level 3.38
2nd Support Level 3.26

See More

52-Week High 4.39
Last Price 3.46
Fibonacci 61.8% 3.30
Fibonacci 50% 2.96
Fibonacci 38.2% 2.62
52-Week Low 1.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar